CREON(R) (Pancrelipase) Delayed-Release Capsules First And Only Pancreatic Enzyme Product To Receive FDA Approval Under New Guidelines Solvay Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (
FDA) approved CREON(R) (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. CREON(R) is the first and only pancreatic enzyme product (PEP) to receive
FDA approval under new guidelines for the class.
Source: www.medicalnewstoday.comHonoring Four Legendary LA BioMed Physician-Researchers In recognition of their distinguished contributions to science, the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) will honor four of its legendary physician-scientists at its sixth annual "Legends" dinner celebration May 12 at Trump National Golf Club. John R. Benfield, MD, David S. Cannom, MD, Larry J. Shapiro, MD, and Mark A.
Source: www.medicalnewstoday.comUSA's Largest Ever Prostate Cancer Screening Programme Shows High Compliance And Consistent Results Just under five per cent of the men who took part in the prostate cancer element of the USA's largest ever cancer screening trial were diagnosed with the disease and the majority of those were picked up by screening programmes, according to research published in the December issue of the UK-based urology journal BJU International.
Source: www.medicalnewstoday.comAccording To Cutting Edge Information, Only 59% Of Pharma Companies Own Dedicated Compliance Departments A new study by business intelligence firm Cutting Edge Information finds that only 59% of pharmaceutical companies currently own dedicated departments for compliance. The study, "Monitoring and Ensuring Pharmaceutical Compliance," highlights the growing need for creating a dedicated compliance department.
Source: www.medicalnewstoday.comProstate Cancer Immunotherapy Significantly Prolongs Survival In Men With Advanced Prostate Cancer Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago. These data from the Phase 3 Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT) study were presented during the meeting's Late Breaking Science Forum. A special session for interested media will take place at 3:00 p.m.
Source: www.medicalnewstoday.com
# posted by Network @ 10:19 PM
